https://www.nice.org.uk/guidance/ta814
Overview | Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic...
Evidence-based recommendations on abrocitinib (Cibinqo), tralokinumab (Adtralza) or upadacitinib (Rinvoq) for treating moderate to severe atopic dermatitis
overviewabrocitinibtralokinumabupadacitinib
https://www.businesswire.com/news/home/20201028006197/en/LEO-Pharma-Presents-Data-for-Tralokinumab-on-Pooled-Safety-S.-aureus-Colonization-Reduction-and-Impact-on-Vaccine-Response-Rates-at-the-29th-Annual-European-Academy-of-Dermatology-and-Venereology-EADV-Virtual-Congress
LEO Pharma Presents Data for Tralokinumab on Pooled Safety, S. aureus Colonization Reduction and...
LEO Pharma A/S, a global leader in medical dermatology, today announced data demonstrating the safety profile for tralokinumab, an investigational, fully hum...